Cargando…

Population Pharmacokinetics of Isavuconazole in Subjects with Mild or Moderate Hepatic Impairment

Isavuconazole, administered as the prodrug isavuconazonium sulfate, was recently approved by the U.S. Food and Drug Administration and the European Medicines Agency for the treatment of adults with invasive aspergillosis and mucormycosis. The objective of this analysis was to develop a population ph...

Descripción completa

Detalles Bibliográficos
Autores principales:	Desai, Amit, Schmitt-Hoffmann, Anne-Hortense, Mujais, Salim, Townsend, Robert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2016
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4862513/ https://www.ncbi.nlm.nih.gov/pubmed/26953193 http://dx.doi.org/10.1128/AAC.02942-15

Ejemplares similares

Phase I trial to investigate the effect of renal impairment on isavuconazole pharmacokinetics
por: Townsend, Robert W., et al.
Publicado: (2017)

Tissue Distribution and Elimination of Isavuconazole following Single and Repeat Oral-Dose Administration of Isavuconazonium Sulfate to Rats
por: Schmitt-Hoffmann, Anne-Hortense, et al.
Publicado: (2017)

Isavuconazole Population Pharmacokinetic Analysis Using Nonparametric Estimation in Patients with Invasive Fungal Disease (Results from the VITAL Study)
por: Kovanda, Laura L., et al.
Publicado: (2016)

Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment
por: Schnell, David, et al.
Publicado: (2014)

Pharmacokinetic and Pharmacodynamic Evaluation of the Drug‐Drug Interaction Between Isavuconazole and Warfarin in Healthy Subjects
por: Desai, Amit, et al.
Publicado: (2016)

Exposure-Response Relationships for Isavuconazole in Patients with Invasive Aspergillosis and Other Filamentous Fungi
por: Desai, Amit V., et al.
Publicado: (2017)

The pharmacokinetics of dalbavancin in subjects with mild, moderate, or severe hepatic impairment
por: Dowell, J, et al.
Publicado: (2008)

Apixaban Pharmacokinetics and Pharmacodynamics in Subjects with Mild or Moderate Hepatic Impairment
por: Frost, Charles E., et al.
Publicado: (2021)

No Dose Adjustment for Isavuconazole Based on Age or Sex
por: Desai, Amit V., et al.
Publicado: (2019)

2537. Population Pharmacokinetics of Isavuconazole in Pediatric Patients
por: Desai, Amit, et al.
Publicado: (2023)

Impact of Mucositis on Absorption and Systemic Drug Exposure of Isavuconazole
por: Kovanda, Laura L., et al.
Publicado: (2017)

QT Interval Shortening With Isavuconazole: In Vitro and In Vivo Effects on Cardiac Repolarization
por: Keirns, J, et al.
Publicado: (2017)

Pharmacokinetic Interactions Between Isavuconazole and the Drug Transporter Substrates Atorvastatin, Digoxin, Metformin, and Methotrexate in Healthy Subjects
por: Yamazaki, Takao, et al.
Publicado: (2016)

The Effect of Posaconazole and Isavuconazole on the Pharmacokinetics of Erdafitinib in Beagle Dogs by UPLC-MS/MS
por: Ruan, Lan-hong, et al.
Publicado: (2021)

Pharmacokinetic Interaction Between Isavuconazole and a Fixed‐Dose Combination of Lopinavir 400 mg/Ritonavir 100 mg in Healthy Subjects
por: Yamazaki, Takao, et al.
Publicado: (2016)

Pharmacokinetics and Safety of Single-Dose Esaxerenone in Japanese Subjects with Mild to Moderate Hepatic Impairment
por: Kurata, Akifumi, et al.
Publicado: (2019)

Pharmacokinetic Effects of Isavuconazole Coadministration With the Cytochrome P450 Enzyme Substrates Bupropion, Repaglinide, Caffeine, Dextromethorphan, and Methadone in Healthy Subjects
por: Yamazaki, Takao, et al.
Publicado: (2016)

2535. Physiological-based pharmacokinetic analysis of drug–drug interactions between isavuconazole and vincristine in pediatric subjects
por: Choules, Mary P, et al.
Publicado: (2023)

Pharmacokinetics of Cabotegravir in Subjects with Moderate Hepatic Impairment
por: Shaik, Jafar Sadik, et al.
Publicado: (2017)

Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics
por: Tortorici, Michael A., et al.
Publicado: (2010)

Effect of mild or moderate hepatic impairment on the pharmacokinetics of risdiplam
por: Kletzl, Heidemarie, et al.
Publicado: (2022)

Pharmacokinetic Evaluation of CYP3A4‐Mediated Drug‐Drug Interactions of Isavuconazole With Rifampin, Ketoconazole, Midazolam, and Ethinyl Estradiol/Norethindrone in Healthy Adults
por: Townsend, Robert, et al.
Publicado: (2016)

Pharmacokinetics and Bioequivalence of Isavuconazole Administered as Isavuconazonium Sulfate Intravenous Solution via Nasogastric Tube or Orally in Healthy Subjects
por: Desai, Amit, et al.
Publicado: (2021)

Dose adjustment not required for contezolid in patients with moderate hepatic impairment based on pharmacokinetic/pharmacodynamic analysis
por: Wu, Junzhen, et al.
Publicado: (2023)

Evaluation of the Pharmacokinetics and Safety of a Single Oral Dose of Fasiglifam in Subjects with Mild or Moderate Hepatic Impairment
por: Marcinak, John, et al.
Publicado: (2018)

Isavuconazole Pharmacokinetics and Pharmacodynamics in Children
por: Elhence, Hirsh, et al.
Publicado: (2022)

Bronchopulmonary penetration of isavuconazole in lung transplant recipients
por: Caballero-Bermejo, Antonio F., et al.
Publicado: (2023)

Pharmacokinetics and Safety of Omadacycline in Subjects with Impaired Renal Function
por: Berg, Jolene K., et al.
Publicado: (2018)

Pharmacodynamics of Isavuconazole in a Rabbit Model of Cryptococcal Meningoencephalitis
por: Kovanda, Laura L., et al.
Publicado: (2019)

Population Pharmacokinetics of Isavuconazole from Phase 1 and Phase 3 (SECURE) Trials in Adults and Target Attainment in Patients with Invasive Infections Due to Aspergillus and Other Filamentous Fungi
por: Desai, Amit, et al.
Publicado: (2016)

Studies on the inhibitory effect of isavuconazole on flumatinib metabolism in vitro and in vivo
por: Liu, Ya-nan, et al.
Publicado: (2023)

Safety and pharmacokinetics of SPR206 in subjects with varying degrees of renal impairment
por: Bruss, Jon B., et al.
Publicado: (2023)

Efficacy and Associated Drug Exposures of Isavuconazole and Fluconazole in an Experimental Model of Coccidioidomycosis
por: Kovanda, Laura L., et al.
Publicado: (2021)

Comparison of the Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Healthy Japanese and Caucasian Subjects
por: Oshima, Hiroyuki, et al.
Publicado: (2015)

Pharmacokinetic Assessment of Drug‐Drug Interactions of Isavuconazole With the Immunosuppressants Cyclosporine, Mycophenolic Acid, Prednisolone, Sirolimus, and Tacrolimus in Healthy Adults
por: Groll, Andreas H., et al.
Publicado: (2016)

A Phase 1, Multicenter, Open-Label Study to Evaluate the Pharmacokinetics of Iberdomide in Subjects with Mild, Moderate, or Severe Hepatic Impairment Compared with Healthy Subjects
por: Cheng, Yiming, et al.
Publicado: (2023)

Population pharmacokinetic/pharmacodynamic analysis of AK111, an IL-17A monoclonal antibody, in subjects with moderate-to-severe plaque psoriasis
por: Li, Qian, et al.
Publicado: (2022)

Safety and Pharmacokinetics of Taniborbactam (VNRX-5133) with Cefepime in Subjects with Various Degrees of Renal Impairment
por: Dowell, James A., et al.
Publicado: (2022)

1320. Pharmacokinetics of Isavuconazole Administered as Isavuconazonium Sulfate Intravenous Solution via Nasogastric Tube or Orally in Healthy Volunteers
por: Desai, Amit, et al.
Publicado: (2020)

Single-Dose Pharmacokinetics of Milvexian in Participants with Mild or Moderate Hepatic Impairment Compared with Healthy Participants
por: Perera, Vidya, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_pp6g8g8qj14rp3i80b5qv5861k